A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Purpose
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Conditions
- Obesity
- Type 2 Diabetes
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
: - Male or female (sex assigned at birth, inclusive of all gender identities). - Age 18 years or above at the time of signing the informed consent. - BMI≥ 35.0 kg/m^2. - Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.
Exclusion Criteria
- A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records. - Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Cagrisema - dose level 1 |
Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks. |
|
|
Active Comparator Cagrisema - dose level 2 |
Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks. |
|
|
Active Comparator Semaglutide |
Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks. |
|
Recruiting Locations
Birmingham, Alabama 35294
Pelham, Alabama 35124
Gilbert, Arizona 85296
Phoenix, Arizona 85006
Little Rock, Arkansas 72205
Little Rock, Arkansas 72211
Escondido, California 92025
Escondido, California 92025
La Mesa, California 91942
Lincoln, California 95648
Loma Linda, California 92354
Los Alamitos, California 90720
Northridge, California 91325
Palm Springs, California 92262
San Diego, California 92111
Van Nuys, California 91405
Walnut Creek, California 94598
Aurora, Colorado 80045
Clearwater, Florida 33761
Fleming Island, Florida 32003
Jacksonville, Florida 32204
Jacksonville, Florida 32205
Miami, Florida 33155
Miami, Florida 33165
Miramar, Florida 33027
Ocoee, Florida 34761
Oviedo, Florida 32765
Pembroke Pines, Florida 33024
Conyers, Georgia 30094
Gainesville, Georgia 30501
Roswell, Georgia 30076
Woodstock, Georgia 30189-4255
Meridian, Idaho 83646
Chicago, Illinois 60607
Gillespie, Illinois 62033
Gurnee, Illinois 60031
Skokie, Illinois 60077
Skokie, Illinois 60077
West Des Moines, Iowa 50266
Newton, Kansas 67114
Topeka, Kansas 66606
Lexington, Kentucky 40503
Buckley, Michigan 49620
Richfield, Minnesota 55423
Belzoni, Mississippi 39038
Chesterfield, Missouri 63005
St Louis, Missouri 63128
West Seneca, New York 14224
Greensboro, North Carolina 27408
Greenville, North Carolina 27834
Morehead City, North Carolina 28557
Morehead City, North Carolina 28557
Statesville, North Carolina 28625
Wilmington, North Carolina 28401
Fargo, North Dakota 58104
Maumee, Ohio 43537
Norman, Oklahoma 73069
Norman, Oklahoma 73072
Hatboro, Pennsylvania 19040
Philadelphia, Pennsylvania 19114
Cumberland, Rhode Island 02864
Gaffney, South Carolina 29340
Spartanburg, South Carolina 29303
Jackson, Tennessee 38305
Kingsport, Tennessee 37660
Memphis, Tennessee 38119
Morristown, Tennessee 37813
Nashville, Tennessee 37203
Amarillo, Texas 79124
Austin, Texas 78731
Austin, Texas 78759
Dallas, Texas 75230
Dallas, Texas 75231
Euless, Texas 76040
Houston, Texas 77040
Houston, Texas 77079
Katy, Texas 77450
Kerrville, Texas 78028
Lampasas, Texas 76550
Laredo, Texas 78041
Longview, Texas 75605
McAllen, Texas 78503
San Antonio, Texas 78209
San Antonio, Texas 78229
San Antonio, Texas 78233
Shavano Park, Texas 78231
Sugar Land, Texas 77478
Salt Lake City, Utah 84109
Salt Lake City, Utah 84121
Sandy City, Utah 84093
South Jordan, Utah 84095
Newport News, Virginia 23606
Newport News, Virginia 23606
Richmond, Virginia 23294
More Details
- Status
- Recruiting
- Sponsor
- Novo Nordisk A/S